tirzepatide 10mg pen GLP1 GIP Mounjaro 10 mg/0.5 mL pre-filled
Description
A 10% or greater weight loss was observed in 60.5% of the 10 mg tirzepatide group and 64.8% of the 15 mg tirzepatide group compared with 9.5% with placebo, and a 15% or greater weight loss was achieved by 39.7% of the 10 mg tirzepatide group and 48% of the 15 mg tirzepatide group compared with 2.7% of the placebo group
Contact the pharmacy for a replacement
Although a fairly large proportion of patients have reported a number of side effects, particularly at the gastrointestinal level (nausea, vomiting, diarrhoea), these side effects tend to diminish over time and adherence to treatment remains high, with about 5% of patients discontinuing treatment due to side effects
This month is about adjustment
To qualify, your provider must clearly document the diagnosis and follow the plans prior authorization steps
